Roche's Ocrelizumab Strengthens Lead In Primary Progressive MS

Sufferers of primary progressive multiple sclerosis (PPMS) - the rarer form of the neurological condition for which there is still no approved treatment - have had their hopes boosted by news Roche's CD20 antibody ocrelizumab won breakthrough therapy designation from the FDA, the first investigational therapy to do so in MS.